Rimonabant / Acomplia Fat Burning Hormones And Smoking Cessation

Rimonabant / Acomplia Fat Loss Hormones and Smoking cessation

Assay: ≥99.5%
CAS: 168273-06-1
MF: C22H21Cl3N4O
Loss on drying: ≤0.5%
pH: (10% solution) 4-7
Heavy metal: ≤10ppm
Melting point: 230 ~ 240 Centigrade
Appearance: White crystal powder

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

How does Acomplia work?

Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle².

Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.

CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system).^3,4 The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.

What is Acomplia used for?

Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.

Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease.

Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.

Other effects

Rimonabant reduces voluntary wheel running in laboratory mice.

Rimonabant significantly increased human sperm motility and viability in vitro.

Rimonabant has been used as a treatment for patients with diabetes.

Negative side effects

Shortly after market introduction, press reports and independent studies suggested that side effects occurred more intensely and more commonly than had been found by the manufacturer in their clinical studies. Reports of severe depression and suicidal thoughts were frequent. As the drug's target CB1 receptors are fairly ubiquitous throughout the central nervous system, it is not currently understood where the inverse agonist is acting to cause these side-effects.

In 2007, it was reported that the committee advising the U.S. FDA had voted not to recommend the drug's approval because of concerns over suicide, depression, and other related side effects associated with use of the drug.

Additional side effects that have been observed by data collection over many years resulted in patients exhibiting: depressive mood, major depression, dysthymia and depressive symptoms, which although they sound very similar they are different in severity and symptoms.

COA:

Any needs, please contact me

Email: tonyraws810@gmail.com

Whatsapp: 86-15871352379

Wickr: tonyraws